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 During the fi rst three decades of clinical 
transplant practice (1960 – 1990), the 
great fear for both patient and clini-
cian was the occurrence of acute rejec-
tion. Th is process not only created the 
opportunity for sudden catastrophic graft  
loss but also set into motion the biologi-
cal processes leading to graft  scarring, 
glomerulopathy, and progressive renal 
dysfunction. Adding to this concern was 
the excess morbidity from opportunistic 
infection that frequently resulted from 
high-dose immunosuppression used to 
reverse such acute-rejection episodes. 
Today such events are distinctly uncom-
mon, thanks primarily to three advances 
in transplant practice: the development 
of sophisticated tissue typing and cross-
matching techniques that have virtually 
eliminated unintentional transplantation 
of kidneys into recipients presensitized 
to donor human leukocyte antigens; 
practices that limit excess immunosup-
pression coupled with more potent and 
selective anti-infective agents; and the 
widespread incorporation of calcineurin 
inhibitor (CNI) drugs into immuno-
suppressive regimens. However, the 
fall in both frequency and intensity of 
early acute rejections, the fi rst 6 months 
aft er transplantation, has not translated 
into improved long-term graft  survival 
beyond 1 – 2 years. 1 
 During the past decade there has been 
a major shift  in the focus of kidney trans-
plant research from the prevention of 
acute rejection to the recognition and tar-
geting of risk factors that associate with 
late graft  loss beyond 1 year. Although 
acute rejection is less formidable today, it 
nevertheless retains its role as an impor-
tant risk factor for late graft  loss. However, 
the demographic reality of an ever 
increasing age of donor kidneys, wait-
listed patients, and eventual transplant 
recipients has now introduced many chal-
lenges and stressors for long-term graft  
survival. 2 It is now apparent that the major 
causes of kidney graft  loss beyond 1 year 
aft er transplantation are progressive dete-
rioration of graft  function, oft en termed 
chronic allograft  nephropathy, the hall-
mark of which is histological evidence of 
tubular atrophy, interstitial fi brosis, and 
transplant glomerulopathy; and patient 
death from cardiovascular disease, oft en 
with a functioning kidney graft . What has 
also emerged is that many of the same risk 
factors associated with the former are also 
associated with the latter. Th ese include 
age; diabetes, both preexisting and occur-
ring aft er the transplantation; poorly con-
trolled hypertension; dyslipidemia; viral 
infections; and diminished allograft  func-
tion. In fact, renal dysfunction (estimated 
glomerular fi ltration rate (eGFR)   <  40 
cc / min) itself appears to be an independ-
ent risk factor for coronary heart disease 
and death. 3 
 A cruel irony that has accompanied 
the control of acute rejection via the 
widespread introduction of CNI drugs 
nearly 30 years ago has been their direct 
and indirect toxicity to the kidney. CNI 
nephrotoxicity appears to target the renal 
microcirculation by promoting pre-
glomerular vasoconstriction, as well as 
direct injury resulting in hyalinosis of 
blood vessels. In addition, CNIs appear 
to favor the progression of post-trans-
plantation hypertension, hyperglycemia, 
dyslipidemia, and oncogenesis, which 
are associated with late morbidity. 
Although variable in severity and oft en 
dose related, CNI nephrotoxicity con-
tributes to the decline in kidney function 
over time. 4 Th e pattern of injury is per-
haps best chronicled in non-transplant 
patients treated for autoimmune disease 
who lost 50 % of their native renal func-
tion and developed histological striped 
fi brosis aft er 2 years of continuous CNI 
use. 5 It has also been demonstrated by 
comparison of 2-year kidney biopsies 
that recipients treated with mycopheno-
late mofetil (MMF) and steroids and the 
mTOR inhibitor sirolimus in lieu of a 
CNI drug had diminished scarring and 
gene expression for fi brosis and tissue 
remodeling. 6 For these reasons, CNI 
dose reduction, elimination, or avoid-
ance has become the focus of numerous 
clinical kidney transplant trials with 
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 The search continues for the best role for mTOR inhibitor drugs in renal 
transplantation — principally to avoid or minimize the nephrotoxicity of 
the CNI class of immunosuppressive agents. The Spare the Nephron Trial 
describes the popular approach of early conversion from a CNI to the 
mTOR agent sirolimus for patients maintained on mycophenolate mofetil 
and steroids. At 1 – 2 years the glomerular filtration rate (GFR) was superior 
for the sirolimus group, with a loss of tolerability for about 20 % . 
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measurements of renal function rather 
than acute rejection as the primary effi  -
cacy end point. 
 Now, the investigators of the Spare the 
Nephron (STN) trial 7 (this issue) report 
the 2-year data from their randomized, 
controlled, multicenter study comparing 
the eff ects of CNI maintenance with the 
effects of  conversion from a CNI 
(cyclosporine or tacrolimus) to the mTOR 
inhibitor sirolimus in kidney recipients 
also maintained on 2  g MMF daily and 
steroids. Th e advantage of this conversion 
approach was the removal of some of the 
undesirable early side eff ects attributed to 
the  de novo use of mTOR inhibitor drugs, 
primarily delayed wound healing and fl uid 
collections. Th e primary effi  cacy end point 
was GFR at 1 and 2 years, measured with 
the use of cold iothalamate. Patients were 
converted between 30 and 180 days aft er 
transplantation, and more than 70 % had 
been given an induction antibody. Impor-
tantly, this was a moderate-risk and 
diverse study population fairly typical of 
urban North American transplant centers; 
60 % of the patients received deceased-
donor kidneys, 23 % were diabetic, 16 % 
were sensitized (percent reactive anti-
body   >  20 % ), and 33 % were African 
American. Important exclusion criteria 
were acute rejection less than 90 days aft er 
randomization, more than one rejection 
episode, and a creatinine level greater than 
2.5  mg / d l  (ca lculated creat inine 
clearance   <  30  cc / min). Sparing the neph-
ron here means sparing it from the 
changes induced by continuous CNI use. 
 Th e major fi nding of this trial is a statis-
tically signifi cant improvement in renal 
function after 1 year for 148 recipients 
converted to sirolimus compared with 151 
recipients remaining on a CNI (iothala-
mate GFR increase from baseline, 24.4 % 
versus 5.2 % ,  P  =  0.01; eGFR increase, 5.2 % 
versus   −  0.9 % ,  P  =  0.05; or calculated cre-
atinine clearance, 4.4 % versus   −  2.3 % , 
 P  =  0.03). Th e diff erences were about the 
same for recipients initiated on tacrolimus 
versus cyclosporine. When analyzed in an 
intention-to-treat fashion at 2 years, the 
diff erences were maintained for recipients 
converted to sirolimus compared with 
recipients remaining on a CNI (iothala-
mate GFR increase, 8.6 % versus 
3.4 % ,  P  =  0.054; eGFR increase, 6.5 % ver-
sus   −  1.8 % ,  P  =  0.04; or calculated 
creatinine clearance, 4.7 % versus   −  4.2 % , 
 P  =  0.02). Of note was the declining GFR at 
2 years in the recipients continued on a CNI. 
A recent report analyzing the change in 
eGFR slopes confi rms that although they 
are improving, they have remained negative 
in recent years ( Figure 1 ). There was no 
apparent outcome penalty for the conver-
sion, with a 2-year rate of biopsy- confi rmed 
acute rejection of 9.5 % versus 11.3 % , a graft -
loss rate of 2 % versus 4 % , and a death rate 
of 0 versus 3.3 % favoring the sirolimus-
treated group. In addition, the sirolimus 
group experienced fewer BK virus and 
cytomegalovirus infections. 
 The strength of this study lies in the 
relatively complete collection of data; the 
use of measured as well as calculated GFR; 
and the targeting of appropriate sirolimus 
trough levels (mean about 8.5 ng / ml). 
These data in large part mirror those 
reported from the similar French CON-
CEPT study. 8 More compelling would 
have been to confi rm the protection of 
kidney histology during this 2-year inter-
val with biopsies. Th e STN investigators 7 
did fi nd a numeric diff erence in tolerabil-
ity in the sirolimus group, with a 19.2 % 
rate of discontinuations for safety indica-
tions compared with 14.3 % in the CNI 
group, although the diff erence was not 
signifi cant. Th ey did fi nd a signifi cant dif-
ference in the reported incidence of dys-
lipidemia, peripheral edema, and mouth 
sores aft er switching to sirolimus. In addi-
tion, there was a clinically similar but sig-
nifi cantly diff erent amount of proteinuria 
at 1 year in the sirolimus group (protein /
 creatinine ratio: sirolimus / MMF group, 
0.6 ± 1.31,  n  =  107, versus CNI / MMF 
group, 0.4 ± 1.07,  n  =  110,  P  =  0.004). 
 A notable observation was a decline in 
the percentage increase in measured GFR 
from baseline at 1 year in the sirolimus /
 MMF versus the CNI / MMF group. By 
inference this implies that the GFR in the 
sirolimus / MMF group decreased. How-
ever, since 41 of 148 sirolimus / MMF 
patients were switched back to a CNI for 
various reasons, they may have experi-
enced a decline in GFR aft er re-exposure 
to a CNI. Th e on-therapy diff erence here 
would be of interest to address the penalty, 
if any, of this double switch. And herein 
lies the clinical conundrum that has 
plagued the widespread discontinuation 
or avoidance of CNI drugs in favor of the 
mTOR inhibitor class of drugs in order to 
tease out improvements in kidney trans-
plant GFR. Is there a problem with safety 
and tolerability in the use of the sirolimus /
 MMF combination compared with the 
CNI / MMF combination that limits the 
GFR advantage? For some patients the 
answer is yes, and this also appears to be 
related to investigator comfort with this 
drug combination as well. 9 
 Early conversion from a CNI to an 
mTOR drug or elimination of a CNI drug 
is associated with an approximately 5 % 
rate of acute rejection, usually low grade, 
reversible, and similar to the result of 
remaining on a CNI, as the STN investiga-
tors report. 7 It is important to initially 
keep patients at a sirolimus C 0 level of 
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 Figure 1  |  GFR slopes from 6 months to 2 years after live-donor and deceased-donor 
renal transplantation in the United States . eGFR, estimated glomerular filtration rate. 
(Reprinted from ref.  12 ) 
commentar y
806   Kidney International (2011) 79 
8 – 12 ng / ml (mean 10 ng / ml) in CNI-free 
regimens. Th is range was confi rmed in a 
meta-analysis of randomized  de novo tri-
als. 9 When subtherapeutic dosing is used, 
as in the Symphony trial, which targeted a 
C 0 level of 4 – 8  ng / ml, rates of acute rejec-
tion up to 40 % may occur. 10 When 
patients tolerate the sirolimus / MMF regi-
men, the renal function oft en improves. 
But this conversion should be done early 
after transplantation before significant 
graft  scarring and / or proteinuria develop. 
When the conversion is done late (beyond 
3 – 4 years), or the graft  exhibits chronic 
Banff 2 scarring, and the eGFR is well 
under 40  cc / min, the improvement in GFR 
is muted, as was found in the CONVERT 
study. 11 Lastly, it may be advisable to 
consider a protocol renal biopsy before 
changing immunosuppression to be cer-
tain that  de novo or recurrent glomerular 
disease, severe interstitial fi brosis, subacute 
rejection, occult antibody-mediated rejec-
tion, viral infection, and so on are not the 
cause of renal dysfunction, which would 
predict a poor result from switching. Th e 
STN trial 7 has confi rmed that the nephron 
can be spared signifi cantly during a 2-year 
window when an mTOR inhibitor is sub-
stituted for a CNI drug with no increase in 
acute rejection. About 20 % of patients did 
not tolerate the switch for various reasons, 
which highlights the need for careful mon-
itoring of recipients. Study of the long-term 
impact of this practice (beyond 5 – 10 years) 
remains a work in progress. 
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